- economic impact
- incidence
- 10-year projection of incidence
- transmissibility
- availability of effective antibiotics
- barriers to prevention
The assessment was focused on domestic impact, but the threat of importing
international antibiotic-resistant pathogens was taken into account in the 10-year
incidence projection. Because antibiotic resistance is a rapidly evolving problem, this
assessment will be revised at least every five years. Examples of findings that could
result in a change in threat status are:- Multidrug-resistant and extensively drug-resistant tuberculosis (MDR and XDR
TB) infections are an increasing threat outside of the United States. In the United
States, infections are uncommon because a robust prevention and control
program is in place. If infection rates of MDR and XDR TB increase within the
U.S., this antibiotic-resistant threat will change from serious to urgent, because it
is transmissible through respiratory secretions, and because treatment options are
very limited. - MRSA infections can be very serious and the number of infections is among the
highest of all antibiotic-resistant threats. However, the number of serious
infections is decreasing and there are multiple effective antibiotics for treating
infections. If MRSA infection rates increase or MRSA strains become more
resistant to other antibiotic agents, then MRSA may change from a serious to an
urgent threat. - Streptococcus pneumoniae (pneumococcus) can cause serious and sometimes
life-threatening infections. Antibiotic resistance significantly affects the ability to
manage these infections. A new version of the pneumococcal conjugate vaccine
(PCV13), introduced in 2010, protects against infections with the most resistant
pneumococcus strains and rates of resistant infections are declining. The extent
to which this trend will continue is unknown, but a significant and sustainable
drop in resistant infection rates could result in this threat being recategorized as
concerning.
- Multidrug-resistant and extensively drug-resistant tuberculosis (MDR and XDR
nancy kaufman
(Nancy Kaufman)
#1